Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932152 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00932152 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 3 participants.
The verdict
NCT00932152, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
Interventions
- DRUG Best supportive care
- DRUG Bevacizumab (Avastin)
- DRUG fulvestrant (Faslodex)
- DRUG anastrozole (Arimidex)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932152
The ClinicalTrials.gov registry entry for NCT00932152 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Best supportive care is the first listed.
NCT00932152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932152 about?
NCT00932152 is a clinical study titled "Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer". This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
What is the current status of trial NCT00932152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00932152?
The interventions under investigation include: Best supportive care (DRUG), Bevacizumab (Avastin) (DRUG), fulvestrant (Faslodex) (DRUG), anastrozole (Arimidex) (DRUG).
Who is sponsoring clinical trial NCT00932152?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.